Gut Microbial Metabolite Crosstalk in Crohn's Disease: Network Pharmacology Unveils Dual‐Axis Pathogenesis and Therapeutic Targets
BioFactors · 2025
DOI: 10.1002/biof.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, 2025. Verfasst von Shiting Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China. Hauptthemen laut MEDLINE: Crohn Disease, Gastrointestinal Microbiome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hainan Province Science and Technology Special Fund.
Abstract (Originalsprache)
Crohn's disease (CD), a chronic inflammatory bowel disorder, is driven by dysregulated interactions between gut microbiota and host metabolism. Here, we developed a computational framework integrating multiomics profiling, network pharmacology, and molecular dynamics simulations to systematically map microbiota‐metabolite‐target‐signaling (M‐M‐T‐S) networks and identify therapeutic candidates. By analyzing gut microbial metabolomics and CD‐associated targets (via SwissTargetPrediction [STP]/SEA), we constructed a protein–protein interaction (PPI) network enriched for 50 intestinal hub targets (IL6, AKT1, PPARG; degree centrality [CD] > 19.4), which orchestrate inflammatory (TNF/IL‐17/TLR, FDR = 3.8 × 10 −12 ) and metabolic (PPAR, FDR = 1.5 × 10 −10 ) pathways. Structure‐based screening (AutoDock Vina/AMBER20) revealed 3‐indolepropionic acid (IPA) as a high‐affinity AKT1 binder (Δ G = −67.4 kJ/mol), while Genipin exhibited robust binding to PTGS2, both validated by 100‐ns dynamics simulations (RMSD < 3.8 Å). Mechanistic network analysis uncovered a dual‐axis regulatory paradigm: a pro‐inflammatory axis ( Clostridium spp.‐derived LPS aggravates Th17 polarization via TLR4/IL‐17 signaling) and a reparative axis ( Faecalibacterium prausnitzii ‐produced butyrate enhances barrier integrity through PPARγ‐mediated NF‐κB suppression). Phylogenetic analysis linked microbial functional traits (e.g., LPS/SCFA synthesis) to evolutionary conservation, highlighting clade‐specific roles in CD progression. Drug‐likeness evaluation (SwissADME/ADMETlab 2.0) prioritized IPA as a lead candidate due to its superior solubility (7.65 mg/mL), nonhepatotoxic profile, and AhR agonism, outperforming Genipin. This study establishes IL6/AKT1/PPARG as central therapeutic hubs and positions IPA for clinical translation. Our framework bridges multiomics integration with precision medicine, offering a scalable strategy to decode microbiome‐driven pathologies and accelerate metabolite‐based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China.
- Gastrointestinal Oncology Department, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
ORCID-Profile: Songlin Zhou
Förderung
- National Natural Science Foundation of China
- Hainan Province Science and Technology Special Fund
Zitieren
APA
Chen, S., Li, Y., Liu, J., Wu, J., Zhao, H., Cao, R., & Zhou, S. (2025). Gut Microbial Metabolite Crosstalk in Crohn's Disease: Network Pharmacology Unveils Dual‐Axis Pathogenesis and Therapeutic Targets. BioFactors. https://doi.org/10.1002/biof.70038
Vancouver
Chen S, Li Y, Liu J, Wu J, Zhao H, Cao R, et al. Gut Microbial Metabolite Crosstalk in Crohn's Disease: Network Pharmacology Unveils Dual‐Axis Pathogenesis and Therapeutic Targets. BioFactors. 2025. doi:10.1002/biof.70038
BibTeX
@article{Chen2025,
author = {Chen, Shiting and Li, Yang and Liu, Jiaxin and Wu, Junmei and Zhao, Huange and Cao, Rong and Zhou, Songlin},
title = {Gut Microbial Metabolite Crosstalk in Crohn's Disease: Network Pharmacology Unveils Dual‐Axis Pathogenesis and Therapeutic Targets},
journal = {BioFactors},
year = {2025},
doi = {10.1002/biof.70038}
}
EUVIMED